Corcept Therapeutics Incorporated (Corcept) recently entered into an amendment to extend its pharmaceutical manufacturer services agreement with Optime Care (Optime) for hyperglycemia drug Korlym to March 31, 2024. Optime will continue to act as the exclusive specialty pharmacy dispensing Korlym in the United States.
In its second quarter earnings call, Corcept projected revenue guidance of $400M-$430M as it stated that leading endocrinologists believe there are more patients with Cushing’s syndrome than was previously thought.
On August 4, 2017, Corcept terminated the pharmaceutical manufacturer services agreement between itself and Dohmen Life Science Services and entered into a distribution services agreement with Optime to provide specialty pharmacy services to Corcept.
The 2017 agreement stated that Optime would provide services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and reporting. Under the terms of the agreement, Optime was to dispense Korlym to patients.
Optime creates partnerships for personalized care with a specific focus on disorders affecting smaller patient communities. Optime’s team of experts in rare disorders works with healthcare providers, payers, biopharmaceutical companies, and patients to implement therapies and support services quickly.
Earlier this year, Optime announced the launch of Copay AdvisorSM, a first-in-class, innovative copay assistance program to proactively address challenges and unmet needs of its drug manufacturer partners. Utilizing proprietary block-chain technology as its backbone, Copay AdvisorSM minimizes potentially negative exposure with co-pay and maximizer programs for pharmaceutical manufacturers.
Takeaway: Optime Care’s patient care and distribution models ensure compliance, satisfaction, and long-term well-being to patients suffering with rare disorders